On the TRAIL to overcome BRAF-inhibitor resistance

6Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BRAF inhibition has been an instant, although short-lasting, success in BRAF-mutated melanoma treatment. Novel data by Berger et al. now suggest that BRAF-inhibitor-mediated "priming to death" facilitates tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. We give an overview about the importance of the crosstalk of extrinsic and mitochondrial apoptotic signaling and propose other combination therapies that may prevent or overcome secondary resistance in melanoma. © 2014 The Society for Investigative Dermatology.

Cite

CITATION STYLE

APA

Geserick, P., Herlyn, M., & Leverkus, M. (2014). On the TRAIL to overcome BRAF-inhibitor resistance. Journal of Investigative Dermatology. Nature Publishing Group. https://doi.org/10.1038/jid.2013.348

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free